Dr. Mihalusova is Vice President of Venture Healthcare at Venrock, where she focuses on biotech and pharmaceutical investments. She brings to Venrock deep experience spanning the entire spectrum of drug development – from preclinical, to marketing approval, to lifecycle management – with a special emphasis on crossing the chasm from discovery to clinical validation. She serves on the Boards of Interdict, KymaThera, and K2, and is a Board Observer at Bright Peak, MBrace, and Tisento.

Prior to joining Venrock in 2020, Dr. Mihalusova was Early Development Program Leader at Celgene and BMS, where she led global development for over a dozen drugs across hematology, oncology, inflammation/immunology, and neurodegenerative diseases – many of which she brought from development candidate nomination, through IND, to clinical proof-of-concept. Among the drugs in her portfolio were protein degraders (mezigdomide, eragidomide), epigenetic modifiers (BETi, LSD1i), bispecifics (PD1xLAG3, CD47xCD20), and several CAR-Ts.

Dr. Mihalusova received her Ph.D. in biochemistry from Harvard University, MBA from Harvard Business School, and Sc.B. in biochemistry from Brown University. She serves on the Key Advisory Board for the HBS Blavatnik Fellowship in Life Sciences Entrepreneurship.

white logo.